10-Q: Centene Reports Solid Q2 2024 Results Amidst Medicaid Redeterminations and Marketplace Growth

Centene Corporation's second quarter results show a 6% year-over-year revenue increase, driven by Marketplace growth, while navigating Medicaid redeterminations.

Summary

• Centene Corporation reported a 6% increase in total revenues year-over-year, reaching $39.8 billion for the second quarter of 2024.
• Premium and service revenues grew by 3% year-over-year to $36.0 billion.
• The health benefits ratio (HBR) was 87.6%, slightly up from 87.0% in the second quarter of 2023.
• The selling, general, and administrative (SG&A) expense ratio improved to 8.0%, compared to 8.7% in the same period last year.
• Adjusted diluted earnings per share (EPS) were $2.42, compared to $2.10 in the second quarter of 2023.
• The company's managed care membership increased slightly by 0.2% year-over-year to 28.5 million members.
• Medicaid membership decreased due to redeterminations, while Marketplace membership saw a significant 34% increase.
• Medicare Prescription Drug Plan (PDP) membership increased by 47% year-over-year, while Medicare Advantage membership declined.
• The company recorded a premium deficiency reserve of $335 million related to the 2024 Medicare Advantage contract year.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company faces challenges with Medicaid redeterminations and Medicare Star ratings, it shows strong growth in the Marketplace and Medicare PDP segments, along with improved cost management. The company's strategic moves and financial performance indicate a stable outlook.

Positives

• The company experienced strong growth in its Marketplace business, with a 34% increase in membership.
• Medicare PDP membership saw a significant 47% year-over-year increase.
• The SG&A expense ratio improved, indicating better cost management.
• The company's adjusted diluted EPS increased year-over-year.
• Centene is actively working to help individuals maintain coverage during Medicaid redeterminations.
• The company has a remaining amount of $4.378 billion available under the stock repurchase program.

Negatives

• Medicaid membership decreased due to redeterminations, impacting overall membership numbers.
• Medicare Advantage membership declined year-over-year.
• The company's HBR increased slightly, driven by higher acuity in Medicaid and Medicare Star rating impacts.
• The company recorded a premium deficiency reserve of $335 million related to the 2024 Medicare Advantage contract year.
• The company experienced a decrease in service revenue due to recent divestitures.

Risks

• Medicaid redeterminations continue to impact membership and revenue.
• Changes in Medicare Star ratings can affect revenue and future growth.
• The company faces competition for providers, broker networks, and contract reprocurements.
• The company must manage its information systems effectively to maintain service levels.
• The company is subject to legal and regulatory proceedings, which could result in substantial damages or penalties.
• The company is exposed to risks related to cyber-attacks and data security incidents.
• The company's investment portfolio is subject to market risks, including interest rate fluctuations.

Future Outlook

Centene expects to receive net dividends from its insurance subsidiaries of approximately $1.2 billion and spend approximately $300 million in additional capital expenditures during the remainder of 2024. The company believes its available cash, cash equivalents, investments, and cash from operations will be sufficient to finance its general operations and capital expenditures for at least 12 months from the date of the filing.

Management Comments

• The company remains focused on delivering access to high-quality, affordable healthcare to all of its members.
• Centene believes it is well-positioned to meet the needs of the changing healthcare landscape.
• The company is committed to navigating evolving regulations.
• Centene is actively engaged to help ensure individuals take the state agency requested action to confirm eligibility in their Medicaid coverage or find other appropriate coverage.
• The company continues the use of data and analytics to optimize its business.
• Centene believes it has both the capacity and capability to successfully navigate industry changes to the benefit of its members, customers, providers and shareholders.

Industry Context

The report highlights Centene's performance amidst significant industry shifts, including Medicaid redeterminations and the expansion of the Health Insurance Marketplace. The company's focus on government-sponsored healthcare programs positions it to capitalize on the increasing demand for affordable healthcare options. The growth in the Marketplace business reflects a broader trend of consumers seeking coverage through the ACA exchanges. The company's strategic positioning in both Medicaid and Medicare markets allows it to navigate regulatory changes and capture market share.

Comparison to Industry Standards

• Centene's HBR of 87.6% is within the typical range for managed care organizations, but the slight increase indicates potential challenges in managing medical costs.
• The improvement in the SG&A expense ratio to 8.0% suggests effective cost management compared to some competitors.
• The 34% growth in Marketplace membership is a strong indicator of success in a competitive market, outperforming some peers.
• The 47% increase in Medicare PDP membership demonstrates Centene's ability to capture market share in this segment.
• The company's adjusted diluted EPS of $2.42 is a positive sign of profitability, but it is important to compare this to other large health insurers such as UnitedHealth Group, Humana, and CVS Health to assess relative performance.
• The premium deficiency reserve of $335 million for Medicare Advantage suggests potential challenges in managing costs in this segment, which is a common issue for many insurers.
• The divestitures of international businesses align with a trend of health insurers focusing on core domestic markets, similar to moves by other large players.

Management Changes

Legal Proceedings

• The company is routinely subjected to legal and regulatory proceedings in the normal course of business.
• These matters can include reviews and investigations by federal and state regulatory agencies, litigation arising out of general business activities, and disputes regarding reinsurance arrangements.
• The company intends to vigorously defend itself against legal and regulatory proceedings.
• The company has reached no-fault settlement agreements related to services previously provided by Envolve Pharmacy Solutions, Inc. with the vast majority of states impacted.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance, stock repurchases, and strategic decisions.
• Employees will be affected by any changes in the company's operations and management.
• Members will be impacted by the company's ability to provide access to quality healthcare.
• Providers will be affected by the company's payment practices and network management.
• Customers will be impacted by the company's ability to provide cost-effective services.

Next Steps

• The company will continue to work with state partners to match rates to acuity post-redeterminations.
• Centene will focus on managing costs in the Medicare Advantage business.
• The company will continue to monitor and navigate evolving regulations.
• Centene will continue to target initiatives to improve productivity, efficiencies and reduced organizational costs.
• The company will evaluate refinancing opportunities.
• The company will complete the sale of Collaborative Health Systems by the end of 2024.

Key Dates

Keywords

Medicaid, Medicare, Marketplace, Health Insurance, Managed Care, Redeterminations, Membership, Revenue, EPS, Star Ratings, Divestiture, HBR, SG&A